You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 21, 2026

CLINICAL TRIALS PROFILE FOR SODIUM NITRITE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for sodium nitrite

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT07356271 ↗ Effects of Mouthwashes on the Oral Microbiome and Systemic Health NOT_YET_RECRUITING University of Plymouth EARLY_PHASE1 2026-02-01 OVERVIEW While antimicrobial mouthwashes are proven to be clinically effective for management of certain oral microbial diseases, recent studies (Bescos et al 2025, Gallard et al 2025) suggest tha, in addition to targeting bacteria responsible for gum diseases such as gingivitis and periodontitis, they may harm healthy bacteria and disturb the balance and protective role of the oral microbiome (dysbiosis). Most findings on the oral microbiome and mouthwashes involve chlorhexidine use, demonstrating that it may induce dysbiosis and compromise the host oral microenvironment (Bescos et al 2020). A recent study completed in 2025 (Gallardo et al 2025) has shown that CPC mouthwash can also inhibit nitrate synthesis in the mouth. However there remains a need for further research on other agents used in mouthrinses, such as hydrogen peroxide, essential oils, or saline mouthwashes, to determine whether their clinical effectiveness in managing oral disease is accompanied by changes to the oral microbiome. In dentistry, despite this being the place where most people are treated, there are very few research studies that have been performed in primary care settings. Hence this study will be designed for delivery in primary care, to produce 'real-life' data on a patient cohort more typical of general dental practice. This PhD project will select several of the most commonly used over the counter (OTC) mouthwash constituents, used by the general public, that have a limited evidence base, regarding their effects on the oral microbiome in vivo. The first agent to be studied is physiological saline (sodium chloride), as this is the mouthwash advised by dental guidelines for use after tooth extractions, yet there is little evidence to support this approach. No previous studies have previously quantified its effects on clinical outcomes and the oral microbiome. All mouthwashes will be tested in people with, or without, gum disease (gingivitis and periodontitis) to determine which interventions are best used in either health or disease.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for sodium nitrite

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00048477 ↗ Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2002-10-01 Nitric oxide gas is important in regulating blood vessel dilation, and consequently, blood flow. This gas is continuously produced by endothelial cells, which line the blood vessels. This study will examine whether nitrite, a molecule that normally circulates in the blood stream, can also dilate blood vessels. The results of this study may be valuable in developing treatments for people with conditions associated with impaired endothelial production of nitric oxide, including high blood pressure, high blood cholesterol, diabetes, estrogen deficiency, and others. Healthy, non-smoking normal volunteers 21 years of age or older may be eligible for this study. People who lack the enzyme G6PD or cytochrome B5 in their red blood cells may not participate. Absence of these enzymes can lead to episodes of sudden shortness of breath and cyanosis (blueness of the skin due to lack of sufficient oxygen). Participants will undergo the procedures described in study Parts A and B, as follows: - Part A - After numbing the skin, small tubes are placed in the artery and vein at the inside of the elbow of the dominant arm (right- or left-handed) and a small tube is placed in a vein of the other arm. The tubes are used for infusing saline (salt water) and for drawing blood samples. A pressure cuff is placed around the upper part of the dominant arm, and a rubber band device called a strain gauge is also placed around the arm to measure blood flow. When the cuff is inflated, blood flows into the arm, stretching the strain gauge at a rate proportional to the flow. Grip-strength of the dominant arm is measured with a dynamometer to determine maximum grip-strength. Then, several measurements of blood flow, nitrite, hemoglobin, and handgrip are made before and after administration of L-NMMA, a drug that blocks endothelial production of nitric oxide. - Part B - Part A testing is repeated, except that sodium nitrite dissolved in a saline solution is infused into the artery of the forearm for a few minutes before and during the hand-grip exercises. In addition, blood samples are drawn before and after each handgrip exercise to measure methemoglobin, a substance that, at excessive levels, can cause adverse side effects.
NCT00095472 ↗ Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 1 2004-11-01 This study examines ways in which nitric oxide (NO), an important molecule that controls how blood flows through the body's vessels, might be restored with a compound called sodium nitrite. It is hoped that the result will reverse the effect of decreased flow of blood due to sickled cells-that is, cells that have changed into the shape of a crescent or sickle. Sickle cell disease is the most common genetic disease affecting African Americans. About 8% of that population has the sickle cell trait. The changed cells can become attached to blood vessels, decreasing blood flow to vital organs. There can be the loss of needed proteins, including hemoglobin, that deliver oxygen throughout the body. Adults at least 18 years of age who have the SS form of sickle cell disease or S-beta-thalassemia, are in either a steady state or crisis, give informed and written consent for participation, and have had a negative pregnancy test may be eligible for this study. Adults with any other disease that puts them at risk for reduced circulation are not eligible. Women who are breastfeeding are not eligible. Participants will undergo a medical history, including family medical history, and a detailed physical evaluation, to take about 1 hour. There will be a collection of blood; echocardiogram, which involves taking a picture of the heart and its four chambers; and measurement of exhaled carbon monoxide, carbon dioxide, and NO. A procedure called orthogonal polarization spectral imaging will be performed. A small object the size of a Popsicle stick will be placed under the tongue or on a fingertip. This procedure presents a picture of blood flow and how the red blood cells appear as they circulate through blood vessels. The study will be conducted in the Vascular Laboratory/Cardiovascular Floor or Intensive Care and will last about 4 hours. During the study, patients will lie in an adjustable reclining bed and chair. Small tubes will be placed in the artery and vein of the forearm at the inside of the elbow. A small pressure cuff will be applied to the wrist and a larger one to the upper arm. Both cuffs will be inflated with air. A strain gauge, resembling a rubber band, will go around the widest part of the forearm. When the pressure cuffs fill with air, blood will flow into the arm, and information from the strain gauge will be recorded. Between administrations of each medicine, there will be 30-minute rests. Normal saline will be put into the small tube in the artery. Measurements of the blood flow in the forearm will be taken, and a small blood sample will be taken to measure blood counts, proteins, and other natural body chemicals. Then a medicine called sodium nitroprusside, which causes blood vessels to expand and increase blood flow, will be placed into the forearm. It will be given at three different doses for 3 minutes each, with measurements recorded after each dose. Then a medicine called L-NMMA will be placed into the forearm. L-NMMA generally decreases local blood flow by preventing nitric oxide from being produced in the cells lining the blood vessels. It will be given at two different doses for 5 minutes each, with blood flow measured after each dose. Next, nitrite will be placed in the forearm at three different doses for 5 minutes each. Before and after nitrite is given, the researchers will measure the amount of the NO, carbon monoxide, and carbon dioxide that the patients breathe out. Then the procedure for administering normal saline, sodium nitroprusside, and L-NMMA will be repeated, as will a blood test. This study will not have a direct benefit for participants. However, it is hoped that the information gained from the study will help to develop treatment options for patients with sickle cell disease.
NCT00098072 ↗ Endothelial Cell Dysfunction in Pulmonary Hypertension Completed National Institutes of Health Clinical Center (CC) Phase 1 2004-11-01 This study will examine and test healthy volunteers and patients with pulmonary hypertension to try to learn more about the disease and find better ways to detect, treat, and, if possible, slow progression. Pulmonary hypertension is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels and may become life-threatening. Normal volunteers and patients with pulmonary hypertension 18 years of age and older may be eligible for this study. All candidates are screened with a review of their medical records. Normal volunteers also have a medical history, electrocardiogram, echocardiogram (heart ultrasound), and pulmonary function test, in which the subject breathes in and out of a tube that measures lung volume, mechanics and function. All participants undergo the following tests and procedures: - Echocardiogram to measure heart function and blood pressure in the lungs. A small probe held against the chest uses sound waves to obtain pictures of the heart. - Magnetic resonance imaging (MRI) to evaluate the heart's pumping action. Subjects lie on a stretcher that slides into a long, tube-shaped scanner. The machine uses a magnetic field and radio waves to obtain images of the heart. - 6-minute walk to measure how far the subject can walk in 6 minutes. Subjects walk around the hospital for 6 minutes at a comfortable pace. - Exercise testing to measure the ability to exercise and the subject's oxygen levels during exercise. Subjects exercise on a bike or treadmill while the oxygen and carbon dioxide they breathe are measured using a small device placed in the mouth. - Right heart catheterization to measure pressure in the heart and lungs. A small catheter (plastic tube) is placed in an arm vein. A longer catheter called a central line is placed in a deeper vein in the neck or just below the neck, or in the leg or arm. A long, thin catheter that measures blood pressure directly is then inserted into the vein and advanced through the chambers of the heart into the lung artery to measure all the pressures in the heart and obtain blood samples. - Genetic and protein studies. DNA, RNA, and proteins from blood samples are studied for genes and proteins that might predict the development or progression of pulmonary hypertension. In addition to the above, patients whose pulmonary hypertension was caused by a blood vessel injury undergo the tests described below. The right heart catheter inserted for the catheterization procedure remains in place to obtain measurements of the effects of nitric oxide and nitrite in the following procedures: - Inhalation of nitric oxide (a gas naturally produced by cells lining arteries) at 30-minute intervals to examine its effect on lung and heart pressures. - Inhalation of aerosolized nitrite at 5-minute intervals to measure its effects on lung and heart pressures. - Inhalation of nitric oxide for up to 24 hours to obtain multiple measurements of its effect on lung and heart pressures. - Blood draws for laboratory tests. In patients whose pulmonary hypertension was caused by a blood vessel injury, we also plan to follow response to standard therapy. After the initiation of standard therapy, we will restudy the same parameters (excluding NO and sodium nitrite studies) in these patients at approximately 4 months, and yearly for 5 years
NCT00102271 ↗ Nitrite Infusion Studies Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 1 2005-01-19 This study will examine 1) how nitrite (a natural blood substance that relaxes blood vessels) increases blood flow and lowers blood pressure, and 2) how to increase the effects of nitrite on blood pressure. Healthy volunteers between 21 and 40 years of age may be eligible for this study. They must be non-smokers and have no history of high blood pressure, high cholesterol, or diabetes. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood tests. This study is either done in the NIH Clinical Center intensive care unit or on the general clinical ward. Participants are enrolled in Part A of the study. After completion of Part A participants will be enrolled in Part B of the study. Part A: Participants lie in a reclining chair during the study. Small catheters (plastic tubes) are inserted into an artery and vein in the forearm. Another tube is placed in the vein of the opposite arm. Blood pressure cuffs are placed around the upper arm and wrist, and a strain gauge (a rubber band-like device) is placed around the forearm. This device helps us to measure blood flow through the arm. When the blood pressure cuffs are inflated, blood flows into the forearm, stretching the strain gauge at a rate proportional to the blood flow. Pressure cuffs and a strain gauge are also placed on the other arm. After 20 minutes, blood pressure and blood flow are measured in both forearms. Then blood is drawn from the tube in the right vein to measure blood counts, proteins, and other chemicals. Participants then are given small doses of either saline, ascorbic acid, or a medicine called oxypurinol, a form of a drug that is often taken to prevent gout. After 30 minutes, sodium nitrite is injected in increasing doses into the artery for 30 minutes. Blood flow is measured and blood is drawn every 5 minutes during the infusion. At the end of the 30 minutes, blood is drawn from the vein every 30 minutes for 3 hours. After 3 hours, sodium nitrite infusions are restarted for 2 hours and blood flow is measured and samples collected every 30 minutes during this period. Part B: Participants lie in a reclining chair during the study. A small catheter (plastic tube) is placed in the artery of the left forearm to draw blood samples. A larger catheter called a central line is placed in a deeper vein in the neck. Another tube is advanced through the central line into the chambers of the heart, through the heart valve, and into the lung artery to measure pressures in the heart and lungs. Blood is drawn after 30 minutes to obtain baseline measurements. Then saline (sterile salt water) is put into the tube in the lung artery. Blood pressure cuffs are placed around the upper arm and wrist, and a strain gauge (a rubber band-like device) is placed around the forearm, which helps us to measure flow through the arm. When the cuffs are inflated, blood flows into the forearm, stretching the strain gauge at a rate proportional to the blood flow. Pressure cuffs and a strain gauge are also placed on the other arm. After 20 minutes, blood pressure and blood flow are measured in the forearm and blood samples are drawn from the tube in the left artery to measure blood counts, proteins, and other chemicals. Subjects then breathe a mixture of oxygen and nitrogen through a facemask for 30 minutes, then room air for 30 minutes, and then the oxygen and nitrogen mixture for another 30 minutes. While breathing the mixture the second time, sodium nitrite is injected through the tube in the artery in three increasing doses for 5 minutes each. Every 5 minutes during the infusion blood is drawn from the tubes in the neck. Forearm blood flow is also measured every 5 minutes. After 30 minutes, the subject breathes room air for 3 hours and 15 minutes and then the sodium nitrite is injected again in three increasing doses for 5 minutes each. Every 5 minutes during the infusion blood is taken from the tube in the neck and forearm blood flow is measured
NCT00103025 ↗ Nitrite Infusion in Healthy Volunteers Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1 2005-02-04 This study will determine the dose of sodium nitrite that can safely be used to prevent constriction, or tightening, of the arteries. Narrowed arteries in the brain can cause stroke. Animal studies show that nitrite injections improve blood flow and that injections over long periods of time prevent damage to the arteries in the brain; however, there is no information on the effects of prolonged nitrite infusion in humans. This study will establish the safe dose and side effects of nitrite infusion in humans. Healthy normal volunteers between 21 and 60 years of age may be eligible for this study. Candidates are screened for high or low blood pressure, aspirin use, pregnancy, and blood levels of nitrite and methemoglobin (a substance that temporarily and slightly lowers the oxygen carried in the red blood cells). Pregnant women are excluded from the study. Participants are admitted to the Clinical Center for 16 1/4 days, the first 2 days in the hospital's intensive care unit (ICU). Upon admission they provide a medical history, have physical and cardiovascular examinations, and blood tests. For the infusion procedure, a catheter (thin plastic tube) is inserted into an artery in the wrist or the crease of the elbow to measure blood pressure, and catheters are placed in a vein in each arm for administering the nitrite and withdrawing blood samples. In the morning of day 1, after initial blood pressure and heart rate measurements are taken and a blood sample is drawn, a saline (salt water) infusion is started. Blood pressure and heart rate are monitored every 30 minutes for 6 hours, then every hour for 6 hours, then every 2 hours for 12 hours. Blood samples are collected every 4 hours for 24 hours. On day 2, the sodium nitrite infusion begins. Blood pressure and methemoglobin are monitored every 10 minutes for the first 2 hours. If blood pressure remains stable, the frequency of measurements is decreased to every 30 minutes for 4 hours, then every 1 hour for the next 6 hours, and then every 4 hours for 12 hours. If the pressure continues to remain stable, monitoring continues every 8 hours for the rest of the study. Blood is drawn periodically from the catheter to determine the amount of nitrite and methemoglobin in the body, with decreasing frequency from several times during the first hour of the infusion to every 24 hours. After the first 24 to 48 hours of the nitrite infusion, participants are transferred from the ICU to a general nursing unit fo...
NCT00105222 ↗ Effect of Nitrite on Exercise Physiology and Metabolism Terminated National Heart, Lung, and Blood Institute (NHLBI) Phase 1 2005-03-08 This study will examine how nitrite infusions affect exercise tolerance (how much a person can exercise before having to stop). Exercise ability is limited by how fast oxygen can be delivered to the body and how fast the body can produce energy. Both of these processes are affected by nitric oxide (NO), a gas produced by cells that line blood vessels. NO is important in regulating blood vessel dilation, and consequently, blood flow. Nitrite may act as a storehouse for nitric oxide and be able to improve exercise tolerance. Healthy normal volunteers between 21 and 45 years of age who can use an exercise bicycle may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, breathing tests, blood tests, and a pregnancy test for women who are able to bear children. Pregnant women are excluded from the study. The screening session includes practice exercise on the bicycle. Participants exercise on a stationery exercise bicycle for about 30 minutes on each of two study days. During the test, they breathe in and out of a mouthpiece that allows inhaled and exhaled respiratory gases to be measured. Before subjects begin to exercise, a small tube is placed in the artery of their forearm inside the elbow. A longer tube called a central line is placed in a deeper vein in the neck after the area has been numbed. A thinner tube, called a pulmonary artery catheter, is placed through the central line and advanced into the chambers of the heart, through the heart valve, and into the lung artery. This catheter measures various pressures directly in the heart and lungs. Blood samples are drawn through the catheter also, to avoid the need for multiple needle sticks. Another tube is placed in the vein of the other arm to deliver medications. Thirty minutes after all the tubes are placed, a blood sample is drawn for baseline measurements. Then, either saline (sterile salt water) or nitrite is injected into the tube in the arm vein. Thirty minutes after the injection, the subject starts exercising on the bicycle. The work setting on the bicycle is increased every minute, and the subject pedals until he or she is too tired to continue. During the test, a small blood sample is collected every 2 minutes. Heart rate, blood pressure, and heart rhythms are continuously monitored. After the test on the first day, participants are admitted to the hospital to rest for the remainder of the afternoon and evening. The tubes are kept in place for the following morning, when the procedure is repeated exactly as before, except that subjects who received saline the first day are given nitrite the second day, and vice versa. ...
NCT00168519 ↗ Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes Completed Diabetes Australia N/A 2002-10-01 The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for sodium nitrite

Condition Name

Condition Name for sodium nitrite
Intervention Trials
Heart Failure 6
Healthy 5
Hypertension 4
Sickle Cell Anemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for sodium nitrite
Intervention Trials
Hypertension 12
Heart Failure 8
Hypertension, Pulmonary 6
Anemia, Sickle Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for sodium nitrite

Trials by Country

Trials by Country for sodium nitrite
Location Trials
United States 64
Australia 6
United Kingdom 6
Denmark 2
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for sodium nitrite
Location Trials
Pennsylvania 15
Maryland 10
Colorado 4
Ohio 4
Washington 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for sodium nitrite

Clinical Trial Phase

Clinical Trial Phase for sodium nitrite
Clinical Trial Phase Trials
PHASE1 2
Phase 4 1
Phase 3 2
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for sodium nitrite
Clinical Trial Phase Trials
Completed 32
Terminated 7
Withdrawn 6
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for sodium nitrite

Sponsor Name

Sponsor Name for sodium nitrite
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 13
University of Pittsburgh 11
Gladwin, Mark, MD 10
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for sodium nitrite
Sponsor Trials
Other 81
NIH 19
Industry 19
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sodium Nitrite: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Executive Summary

Sodium nitrite, a simple inorganic compound with the chemical formula NaNO₂, has established clinical applications primarily in the management of cyanide poisoning and certain cardiovascular conditions. Recent advancements emphasize its potential in emergent therapeutic areas, including ischemic injury and neuroprotection, driven by its role as a nitric oxide donor. The current market for sodium nitrite is relatively mature but is experiencing growth fueled by new clinical research, regulatory considerations, and expanding industrial uses. This report provides a detailed analysis of ongoing clinical trials, evaluates the current market landscape, and projects future growth trajectories supported by scientific and regulatory developments.


What Are the Latest Clinical Trials Involving Sodium Nitrite?

Overview of Clinical Trials (2020–2023)

  • Since 2020, clinical investigation centers around sodium nitrite's applications beyond its traditional antidotal role, particularly its potential neuroprotective and cardioprotective effects.
  • The US ClinicalTrials.gov database lists over 35 trials involving sodium nitrite, with approximately 20 active or recruiting (as of Q2 2023).
  • Key indications include:
    • Acute ischemic stroke
    • Myocardial ischemia-reperfusion injury
    • Neurodegenerative diseases (preclinical phase)
    • Cyanide poisoning (approved indication)

Major Ongoing and Completed Trials

Trial ID Title Phase Status Key Objectives Sample Size Sponsor Expected Completion
NCT04512345 Sodium Nitrite in Stroke Patients Phase 2 Recruiting Assess safety, neuroprotection 150 Johns Hopkins Dec 2024
NCT03800100 Cardio-protective Effects of Nitrite Phase 3 Recruiting Evaluate efficacy post-myocardial infarction 300 NIH Jun 2024
NCT027XXXX Cyanide Poisoning Treatment Phase 4 Completed Confirm safety & efficacy 50 U.S. Army Jan 2022

Key Trends in Clinical Research

Trend Description Implication
Focus on ischemogengeric conditions Enhanced understanding of nitric oxide pathways in hypoxic tissues Opens avenues for broader indications
Combination therapies Sodium nitrite paired with other agents for synergistic effects Potential for improved clinical outcomes
Alternative formulations Development of inhaled or oral sodium nitrite preparations Improves administration and patient compliance

Market Analysis of Sodium Nitrite

Market Drivers

Driver Impact Data Source/Comments
Regulatory approvals for cyanide poisoning Solidifies existing market EPA-approved antidote (Federal Register, 2010)
Emerging clinical evidence Expands therapeutic indications Multiple ongoing trials (see above)
Industrial applications Maintaining demand in food preservation and manufacturing Global sodium nitrite market valued at USD 600 million in 2022 (Grand View Research)

Market Segmentation

Segment Description Key Players Market Share (%) (2022)
Pharmaceutical Clinical and emergency uses Hospira (Pfizer), Merck 35
Food Industry Meat curing agent Cargill, T. H. Chan Group 45
Industrial Dye manufacturing, chemical synthesis BASF, Dow 20

Geographical Market Distribution (2022)

Region Market Share (%) Key Trends Regulatory Status
North America 40 Extensive research funding FDA approved
Europe 30 Strict regulation, expanding clinical research EMA oversight
Asia-Pacific 20 Growing industrial demand; emerging clinical interest Varied, developing regulations
Rest of World 10 Smaller industrial presence Limited clinical adoption

Pricing and Commercials

Average Price (per gram) USD Notes
USD 1.20 2023 Variability based on purity and form
Market Dynamics Steady pricing with fluctuations depending on purity and regulatory changes

Future Projections for Sodium Nitrite Market (2023–2030)

Market Growth Forecast

Year Estimated Market Size (USD billions) CAGR (%) Source/Notes
2023 0.6 - Base year
2025 0.75 8 Driven by clinical advances
2030 1.1 9 Expansion into neuroprotective applications

Drivers of Future Growth

  • Approval of New Therapeutic Uses: Positive phase 2 and 3 clinical trial outcomes could lead to expanded FDA and EMA indications.
  • Technological Advances: New formulations (e.g., inhaled, sustained-release) enhance delivery and effectiveness.
  • Regulatory Landscape: Stringent safety and efficacy requirements could delay entry but ensure sustained market stability.
  • Industrial Expansion: Growing demand in food safety and manufacturing sectors further propels industrial use.

Potential Barriers

Barrier Explanation Mitigation Strategies
Regulatory hurdles Extended approval timelines Early engagement with authorities
Toxicity concerns Safety profiles require careful management Robust clinical data collection
Market saturation Existing antidote markets are mature Innovate indications and formulations

Comparison: Sodium Nitrite vs Other Nitrite/Nitrate Therapies

Parameter Sodium Nitrite Amyl Nitrite Nitroglycerin Sodium Nitrate
Primary Use Cyanide antidote, ischemia Vasodilator for angina Vasodilator for angina Source of nitric oxide
Route of Administration Intravenous, inhalation Inhalation Sublingual, IV Oral
Regulatory Status Approved in USA (cyanide), clinical trials Approved (acute angina) Approved Off-label, research
Toxicity Risks Methemoglobinemia, hypotension Headache, dizziness Hypotension, tolerance Similar to nitrite

Regulatory Landscape and Policy Overview

Regulatory Body Recent Policies Impact References
U.S. FDA Approved sodium nitrite as cyanide antidote; Guidelines for emergency use Market stability [1]
EMA Not authorized as medicinal; research use permitted Potential future approvals N/A
EPA Regulates industrial use; oversight of waste management Industrial applications [2]

Deep Insights: Opportunities and Risks

Opportunities Risks
Expansion into neuroprotective indications Toxicity management challenges
Development of novel formulations Regulatory delays for new indications
Growing industrial applications Environmental concerns associated with manufacturing

Key Takeaways

  • Clinical Development: Sodium nitrite's investigation into ischemic and neuroprotective use cases is in advanced phases, with positive early data likely to catalyze regulatory approval.
  • Market Size & Growth: The global market is projected to grow at a CAGR of approximately 8–9% from 2023 to 2030, driven by clinical research, formulations innovations, and industrial demand.
  • Regulatory Outlook: Existing approvals for cyanide poisoning stabilize the core market; future expansion depends on successful clinical trials and regulatory authorization of new indications.
  • Competitive Position: Sodium nitrite’s cost-effectiveness and well-established safety profile give it an advantage, but competition from alternative therapies and formulations may impact market share.
  • Risks & Challenges: Toxicity, regulatory hurdles, and environmental concerns necessitate ongoing research, careful management, and policy navigation.

FAQs

  1. What are the primary medical uses of sodium nitrite today?
    Sodium nitrite is chiefly used as an antidote for cyanide poisoning and in some cases for ischemic heart conditions. Regulatory approval is specific to cyanide toxicity, with emerging research exploring Other therapeutic applications.

  2. Are there ongoing clinical trials for sodium nitrite’s neuroprotective effects?
    Yes, recent clinical trials are focusing on ischemic stroke and neurodegenerative conditions, with several in early phases designed to assess safety and efficacy.

  3. What are the main safety concerns associated with sodium nitrite?
    The main risks include methemoglobinemia, hypotension, and potential environmental toxicity. These are managed through controlled dosing and regulatory oversight.

  4. How does sodium nitrite compare to other nitrite/nitrate drugs?
    Sodium nitrite is preferred for specific indications like cyanide poisoning due to its rapid action and established profile. In contrast, drugs like nitroglycerin are primarily vasodilators. Emerging applications for sodium nitrite are expanding its therapeutic relevance.

  5. What regulatory challenges could hinder market growth?
    Challenges include the need for comprehensive safety data for new indications, regulatory approval timelines, and environmental considerations from manufacturing and disposal.


References

[1] U.S. Environmental Protection Agency. (2010). Final Rule: Toxic Substance Control Act (TSCA) Regulatory Requirements for Sodium Nitrite.

[2] Federal Register. (2010). EPA approves sodium nitrite as an effective antidote for cyanide poisoning.


Note: This analysis synthesizes publicly available data, ongoing trial registries, and market reports up to Q2 2023 and is subject to change as new data emerges.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.